Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 &1 mg

Naman Bansal August 7, 2025 PR

This is the group’s first NoC approval in Canada
 Ahmedabad, India, August 7, 2025
Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received NOC (Notice of Compliance) from Health Canada for ZDS-Varenicline tablets 0.5 &1 mg. This is the group’s first NOC approval in Canada.
Varenicline is used as an aid in smoking cessation. It is a partial nicotinic acetylcholine receptor agonist, designed to partially activate this system while displacing nicotine at its sites of action in the brain.
ZDS-Varenicline tablets will be produced at Zydus Lifescience Ltd, SEZ, Ahmedabad. Varenicline tablets had annual sales of 15 mn Canadian dollar in Canada (IQVIA MAT December 2024).

Check Also

The Cascades Neopolis Partners with Spa L’Occitane en Provence to Bring a Provençal Vision of Better-Being to Residential Living in Hyderabad

Hyderabad, 30th June 2026: The Cascades Neopolis, a ₹3,169 crore residential project by GHR Lakshmi …